Search Results - "GREVER, M. R"

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer by Chu, B. F., Karpenko, M. J., Liu, Z., Aimiuwu, J., Villalona-Calero, M. A., Chan, K. K., Grever, M. R., Otterson, G. A.

“…Purpose Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer and is the most common cause of cancer death in industrialized countries…”
Get full text

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells by Johnson, A J, Yeh, Y-Y, Smith, L L, Wagner, A J, Hessler, J, Gupta, S, Flynn, J, Jones, J, Zhang, X, Bannerji, R, Grever, M R, Byrd, J C

“…The cyclin dependent kinase (CDK) inhibitor flavopiridol has demonstrated promising clinical results in relapsed CLL patients leading to efforts to develop…”
Get full text

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol by Blum, K A, Ruppert, A S, Woyach, J A, Jones, J A, Andritsos, L, Flynn, J M, Rovin, B, Villalona-Calero, M, Ji, J, Phelps, M, Johnson, A J, Grever, M R, Byrd, J C

“…Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor,…”
Get full text

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells by LUCAS, D. M, DAVIS, M. E, GREVER, M. R, PARTHUN, M. R, MONE, A. P, KITADA, S, CUNNINGHAM, K. D, FLAX, E. L, WICKHAM, J, REED, J. C, BYRD, J. C

“…MS-275 is a histone deacetylase (HDAC) inhibitor that has been reported to mediate its cytotoxic effect through generation of reactive oxygen species (ROS) in…”
Get full text

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells by KLISOVIC, M. I, MAGHRABY, E. A, RUSH, L. J, PLASS, C, GREVER, M. R, BYRD, J. C, MARCUCCI, G, PARTHUN, M. R, GUIMOND, M, SKLENAR, A. R, WHITMAN, S. P, CHAN, K. K, MURPHY, T, ANON, J, ARCHER, K. J

“…In t(8;21) acute myeloid leukemia (AML), the AML1/ETO fusion protein promotes leukemogenesis by recruiting histone deacetylase (HDAC) and silencing AML1target…”
Get full text

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity by Byrd, J C, Murphy, T, Howard, R S, Lucas, M S, Goodrich, A, Park, K, Pearson, M, Waselenko, J K, Ling, G, Grever, M R, Grillo-Lopez, A J, Rosenberg, J, Kunkel, L, Flinn, I W

“…Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associated with…”
Get full text

Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study by Leith, Catherine P., Kopecky, Kenneth J., Chen, I-Ming, Eijdems, Lisette, Slovak, Marilyn L., McConnell, Thomas S., Head, David R., Weick, James, Grever, Michael R., Appelbaum, Frederick R., Willman, Cheryl L.

“…Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML). Such resistance has been associated with rapid drug efflux…”
Get full text

Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor by ORLOWSKI, R. Z, ESWARA, J. R, LAFOND-WALKER, A, GREVER, M. R, ORLOWSKI, M, DANG, C. V

“…Cell growth and viability are dependent on the function of the multicatalytic proteinase complex (proteasome), a multisubunit particle that affects progression…”
Get full text

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia by Flynn, J, Jones, J, Johnson, A J, Andritsos, L, Maddocks, K, Jaglowski, S, Hessler, J, Grever, M R, Im, E, Zhou, H, Zhu, Y, Zhang, D, Small, K, Bannerji, R, Byrd, J C

“…Dinaciclib (SCH727965) is a selective CDKi chosen for clinical development based upon a favorable therapeutic index in cancer xenograft models. We performed a…”
Get full text

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 by BYRD, J. C, SHINN, C, WASELENKO, J. K, FUCHS, E. J, LEHMAN, T. A, NGUYEN, P. L, FLINN, I. W, DIEHL, L. F, SAUSVILLE, E, GREVER, M. R

“…Flavopiridol has been reported to induce apoptosis in lymphoid cell lines via downregulation of bcl-2. The in vitro activity of flavopiridol against human…”
Get full text

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia by LIN, T. S, FLINN, I. W, LUCAS, M. S, PORCU, P, SICKLER, J, MORAN, M. E, LUCAS, D. M, HEEREMA, N. A, GREVER, M. R, BYRD, J. C

“…Alemtuzumab (anti-CD52; Campath-1H) is effective in fludarabine-refractory chronic lymphocytic leukemia (CLL), but is associated with infection and early onset…”
Get full text

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin by Flinn, Ian W., Kopecky, Kenneth J., Foucar, M. Kathryn, Head, David, Bennett, John M., Hutchison, Robert, Corbett, William, Cassileth, Peter, Habermann, Thomas, Golomb, Harvey, Rai, Kanti, Eisenhauer, Elizabeth, Appelbaum, Frederick, Cheson, Bruce, Grever, Michael R.

“…The nucleoside analogue, pentostatin, has demonstrated high complete response rates and long relapse-free survival times in patients with hairy cell leukemia,…”
Get full text

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease by Nousari, Hossein C., Brodsky, Robert A., Jones, Richard J., Grever, Michael R., Anhalt, Grant J.

“…Paraneoplastic pemphigus (PNP) is a refractory and life-threatening autoimmune mucocutaneous disease. We have recently reported the effectiveness and safety of…”
Get full text

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia : a previously unrecognized form of acute leukemia potentially misdiagnosed as french-american-british acute myeloid leukemia-M3 by SCOTT, A. A, HEAD, D. R, WAXMAN, S, WHALEN, M. M, BANKHURST, A. D, RICHTER, L. C, GROGAN, T. M, WILLMAN, C. L, KOPECKY, K. J, APPELBAUM, F. R, THEIL, K. S, GREVER, M. R, I-MING CHEN, WHITTAKER, M. H, GRIFFITH, B. B, LICHT, J. D

“…We have identified and characterized a previously unrecognized form of acute leukemia that shares features of both myeloid and natural killer (NK) cells. From…”
Get full text

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity by Callahan, K P, Minhajuddin, M, Corbett, C, Lagadinou, E D, Rossi, R M, Grose, V, Balys, M M, Pan, L, Jacob, S, Frontier, A, Grever, M R, Lucas, D M, Kinghorn, A D, Liesveld, J L, Becker, M W, Jordan, C T

“…Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study…”
Get full text

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features by Woyach, J A, Lozanski, G, Ruppert, A S, Lozanski, A, Blum, K A, Jones, J A, Flynn, J M, Johnson, A J, Grever, M R, Heerema, N A, Byrd, J C

Get full text

The Taxol Supply Crisis. New NCI Policies for Handling the Large-Scale Production of Novel Natural Product Anticancer and Anti-HIV Agents by Cragg, Gordon M, Schepartz, Saul A, Suffness, Matthew, Grever, Michael R

“…Over the past 30 years, the National Cancer Institute has been involved in the preclinical and/or clinical evaluation of the majority of those agents approved…”
Get full text

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia by Cheson, B D, Cassileth, P A, Head, D R, Schiffer, C A, Bennett, J M, Bloomfield, C D, Brunning, R, Gale, R P, Grever, M R, Keating, M J

“…The National Cancer Institute (NCI) sponsored a workshop to develop a set of standardized diagnostic and response criteria for acute myeloid leukemia (AML)…”
Get more information

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center by Stephens, D M, Ruppert, A S, Jones, J A, Woyach, J, Maddocks, K, Jaglowski, S M, Andritsos, L A, Flynn, J M, Grever, M R, Lozanski, G, Johnson, A J, Muthusamy, N, Heerema, N A, Byrd, J C

Get full text

Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton by Senderowicz, A M, Kaur, G, Sainz, E, Laing, C, Inman, W D, Rodríguez, J, Crews, P, Malspeis, L, Grever, M R, Sausville, E A

“…Jasplakinolide, a cyclodepsipeptide produced by an Indo-Pacific sponge, Jaspis johnstoni, has been reported to inhibit the growth of breast cancer cells. The…”
Get more information